Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
NCT00615693 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13
Last updated 2020-12-22
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.
Conditions
- Uveitis
- Posterior Uveitis
- Panuveitis
Interventions
- DRUG
-
AEB071
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Novartis investigator site
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-07-31
- Primary Completion
- 2009-10-31
Countries
- United States
Study Locations
More Related Trials
-
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01090310 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
NCT05523765 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
NCT04706741 ·Status: COMPLETED ·Phase: PHASE2
-
Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis
NCT01603355 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
NCT02218177 ·Status: COMPLETED
-
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
NCT00404612 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema
NCT06771271 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
NCT03155243 ·Status: COMPLETED
-
Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
NCT00525902 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
NCT01327664 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
NCT02764697 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
NCT00006188 ·Status: COMPLETED
-
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
NCT01526889 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
NCT07218770 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
NCT01900431 ·Status: COMPLETED ·Phase: PHASE2
-
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)
NCT02931175 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis
NCT05105347 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
NCT01846299 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
NCT02706704 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy
NCT06821971 ·Status: ACTIVE_NOT_RECRUITING
-
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
NCT00404885 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
NCT02258854 ·Status: TERMINATED ·Phase: PHASE3
-
Microbiome as a ThErapeutic Response Biomarker
NCT04721743 ·Status: WITHDRAWN
-
Leflunomide to Treat Uveitis
NCT00001863 ·Status: COMPLETED ·Phase: PHASE2